Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD73-overexpressing adipose-derived stem cells
- Development stage
- Preclinical
- Lead developer
- The Affiliated Hospital of Qingdao University
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intralesional
01
Overview
CD73-overexpressing adipose-derived stem cells (CD73+ADSCs) are genetically engineered mesenchymal stem cells designed to overexpress ecto-5'-nucleotidase (CD73). CD73 is the rate-limiting enzyme that catalyzes the conversion of extracellular adenosine monophosphate (AMP) to adenosine, a key immunoregulatory and tissue-protective purinergic signaling molecule. By enhancing extracellular adenosine production, these engineered stem cells activate adenosine receptor signaling (specifically A2A and A2B receptors), which suppresses inflammatory pathways (such as NF-κB and NLRP3 inflammasome activation), promotes macrophage polarization toward an anti-inflammatory M2 phenotype, and stimulates autophagy and tissue regeneration. This cell therapy is being investigated in preclinical models for the treatment of neurogenic bladder and tissue repair.
- Other names
- CD73+/+ADSCsCD73+ADSCsCD73-overexpressing ADSCsCD-73-overexpressing ADSCsCD 73-overexpressing ADSCsCD73-overexpressing adipose-derived mesenchymal stem cellsCD-73-overexpressing adipose-derived mesenchymal stem cellsCD 73-overexpressing adipose-derived mesenchymal stem cells
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA2B (Adenosine A2B receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on CD73-overexpressing adipose-derived stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD73-overexpressing adipose-derived stem cells.